Prescient Therapeutics (ASX: PTX) Managing Director and CEO Steven Yatomi-Clarke presents at the Switzer Small & Micro Cap Investor Day July 2022. Steven provides a brief overview of the company’s innovative targeted cell therapies, next generation cell therapy platforms OmniCAR and CellPryme, and how these innovative technologies can change the game for cancer treatments.
Watch the full interview below.